Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 03-Apr-24 4:03 PM View:  | Rizvi Syed Ali-Aamir Chief Medical Officer | Poseida Therapeutics, Inc. (PSTX) | 01-Apr-24 | Grant | 185,000 | -- | -- | 100% 0 to 185.0K | |
| 04-Mar-24 5:18 PM View: | Leonhardt Harry J GC & Chief Compliance Officer | Poseida Therapeutics, Inc. (PSTX) | 01-Mar-24 | Grant | 80,743 | -- | -- | 54% 150.2K to 230.95K | |
| 04-Mar-24 5:18 PM View: | Warner Brent President, Gene Therapy | Poseida Therapeutics, Inc. (PSTX) | 01-Mar-24 | Grant | 80,743 | -- | -- | 22% 374.04K to 454.78K | |
| 04-Mar-24 5:18 PM View: | Leonhardt Harry J GC & Chief Compliance Officer | Poseida Therapeutics, Inc. (PSTX) | 01-Mar-24 | Payment of Exercise | 16,306 | $4.13 | $67,343.80 | (7%) 230.95K to 214.64K | |
| 04-Mar-24 5:18 PM View: | Warner Brent President, Gene Therapy | Poseida Therapeutics, Inc. (PSTX) | 01-Mar-24 | Payment of Exercise | 35,739 | $4.13 | $147,602.00 | (8%) 454.78K to 419.04K | |
| 04-Mar-24 5:29 PM View: | Mylet Johanna Chief Financial Officer | Poseida Therapeutics, Inc. (PSTX) | 01-Mar-24 | Grant | 80,743 | -- | -- | 44% 183.63K to 264.37K | |
| 04-Mar-24 5:18 PM View: | Gergen Mark J Executive Chairman Director | Poseida Therapeutics, Inc. (PSTX) | 01-Mar-24 | Payment of Exercise | 34,157 | $4.13 | $141,068.00 | (5%) 685.45K to 651.29K | |
| 04-Mar-24 5:29 PM View: | Mylet Johanna Chief Financial Officer | Poseida Therapeutics, Inc. (PSTX) | 01-Mar-24 | Payment of Exercise | 18,091 | $4.13 | $74,715.80 | (7%) 264.37K to 246.28K | |
| 02-Feb-24 8:51 PM View: | Gergen Mark J Executive Chairman Director | Poseida Therapeutics, Inc. (PSTX) | 01-Feb-24 | Payment of Exercise | 47,162 | $3.41 | $160,822.00 | (6%) 732.61K to 685.45K | |
| 04-Jan-24 4:02 PM View: | Gergen Mark J Executive Chairman Director | Poseida Therapeutics, Inc. (PSTX) | 02-Jan-24 | Grant | 125,000 | -- | -- | 21% 607.61K to 732.61K | |
| 04-Jan-24 4:03 PM View: | Yarema Kristin President and CEO Director | Poseida Therapeutics, Inc. (PSTX) | 02-Jan-24 | Grant | 250,000 | -- | -- | 70% 356.84K to 606.84K | |
| 16-Jun-23 4:07 PM View: | Corning Luke Director | Poseida Therapeutics, Inc. (PSTX) | 15-Jun-23 | Grant | 19,650 | -- | -- | 100% 19.65K to 39.3K | |
| 16-Jun-23 4:08 PM View: | Baum Charles M Director | Poseida Therapeutics, Inc. (PSTX) | 15-Jun-23 | Grant | 19,650 | -- | -- | 50% 39.3K to 58.95K | |
| 16-Jun-23 4:10 PM View: | Collins Cynthia Director | Poseida Therapeutics, Inc. (PSTX) | 15-Jun-23 | Grant | 19,650 | -- | -- | 100% 19.65K to 39.3K | |
| 16-Jun-23 4:09 PM View: | Schmid John P. Director | Poseida Therapeutics, Inc. (PSTX) | 15-Jun-23 | Grant | 19,650 | -- | -- | 100% 19.65K to 39.3K | |
| 16-Jun-23 4:09 PM View: | Lloyd Marcea Bland Director | Poseida Therapeutics, Inc. (PSTX) | 15-Jun-23 | Grant | 19,650 | -- | -- | 66% 29.65K to 49.3K | |
| 02-May-23 4:14 PM View: | Amado Rafael Director | Poseida Therapeutics, Inc. (PSTX) | 01-May-23 | Grant | 39,300 | -- | -- | 100% 0 to 39.3K | |
| 12-Apr-23 4:49 PM View: | Yarema Kristin President, Cell Therapy | Poseida Therapeutics, Inc. (PSTX) | 11-Apr-23 | Grant | 356,836 | -- | -- | 100% 0 to 356.84K | |
| 02-Mar-23 6:28 PM View: | Mylet Johanna Chief Financial Officer | Poseida Therapeutics, Inc. (PSTX) | 01-Mar-23 | Payment of Exercise | 4,323 | $5.35 | $23,128.00 | (2%) 181.95K to 177.63K | |
| 02-Mar-23 6:26 PM View: | Leonhardt Harry J GC & Chief Compliance Officer | Poseida Therapeutics, Inc. (PSTX) | 01-Mar-23 | Grant | 92,772 | -- | -- | 166% 55.75K to 148.53K | |
| 02-Mar-23 6:17 PM View: | Gergen Mark J President and CEO Director | Poseida Therapeutics, Inc. (PSTX) | 01-Mar-23 | Grant | 269,586 | -- | -- | 81% 332.02K to 601.61K | |
| 02-Mar-23 6:30 PM View: | Warner Brent President, Gene Therapy | Poseida Therapeutics, Inc. (PSTX) | 01-Mar-23 | Grant | 92,772 | -- | -- | 30% 307.88K to 400.65K | |
| 02-Mar-23 6:26 PM View: | Leonhardt Harry J GC & Chief Compliance Officer | Poseida Therapeutics, Inc. (PSTX) | 01-Mar-23 | Payment of Exercise | 4,323 | $5.35 | $23,128.00 | (3%) 148.53K to 144.2K | |
| 02-Mar-23 6:30 PM View: | Warner Brent President, Gene Therapy | Poseida Therapeutics, Inc. (PSTX) | 01-Mar-23 | Payment of Exercise | 26,617 | $5.35 | $142,401.00 | (7%) 400.65K to 374.04K | |
| 02-Mar-23 6:28 PM View: | Mylet Johanna Chief Financial Officer | Poseida Therapeutics, Inc. (PSTX) | 01-Mar-23 | Grant | 92,772 | -- | -- | 104% 89.18K to 181.95K | |
| 03-Feb-23 4:16 PM View: | Gergen Mark J President and CEO Director | Poseida Therapeutics, Inc. (PSTX) | 01-Feb-23 | Payment of Exercise | 31,819 | $7.00 | $222,733.00 | (9%) 362.13K to 330.31K | |
| 03-Feb-23 4:19 PM View: | Ostertag Eric Director | Poseida Therapeutics, Inc. (PSTX) | 01-Feb-23 | Payment of Exercise | 11,776 | $7.00 | $82,432.00 | (< 1%) 6.04M to 6.03M | |
| 10-Aug-22 6:13 PM View: | Ostertag Eric Executive Chairman Director 10% Owner | Poseida Therapeutics, Inc. (PSTX) | 08-Aug-22 | Private Purchase (Planned) | 142,857 | $3.50 | $500,000.00 | 2% 9.26M to 9.4M | |
| 10-Aug-22 8:49 PM View: | Malin Life Sciences Holding... 10% Owner | Poseida Therapeutics, Inc. (PSTX) | 08-Aug-22 | Private Purchase | 2,150,000 | $3.50 | $7,525,000.00 | 22% 9.69M to 11.84M | |
| 05-Aug-22 4:09 PM View: | Ostertag Eric Executive Chairman Director 10% Owner | Poseida Therapeutics, Inc. (PSTX) | 03-Aug-22 | Sale (Planned) | 160,696 | $3.69 | $592,808.00 | (2%) 9.42M to 9.26M | |
| 17-Jun-22 10:44 AM View: | Collins Cynthia Director | Poseida Therapeutics, Inc. (PSTX) | 16-Jun-22 | Grant | 19,650 | -- | -- | 100% 0 to 19.65K | |
| 16-Jun-22 8:56 PM View: | Schmid John P. Director | Poseida Therapeutics, Inc. (PSTX) | 16-Jun-22 | Grant | 19,650 | -- | -- | 100% 0 to 19.65K | |
| 16-Jun-22 8:54 PM View: | Lloyd Marcea Bland Director | Poseida Therapeutics, Inc. (PSTX) | 16-Jun-22 | Grant | 19,650 | -- | -- | 197% 10.0K to 29.65K | |
| 16-Jun-22 8:57 PM View: | Corning Luke Director | Poseida Therapeutics, Inc. (PSTX) | 16-Jun-22 | Grant | 19,650 | -- | -- | 100% 0 to 19.65K | |
| 16-Jun-22 8:59 PM View: | Baum Charles M Director | Poseida Therapeutics, Inc. (PSTX) | 16-Jun-22 | Grant | 39,300 | -- | -- | 100% 0 to 39.3K | |
| 18-Mar-22 8:01 PM View: | Ingalls Kerry D. Chief Operating Officer | Poseida Therapeutics, Inc. (PSTX) | 16-Mar-22 | Private Purchase | 3,000 | $3.98 | $11,940.00 | 6% 52.0K to 55.0K | |
| 01-Mar-22 10:00 PM View: | Warner Brent President, Gene Therapy | Poseida Therapeutics, Inc. (PSTX) | 01-Mar-22 | Grant | 307,881 | -- | -- | 100% 0 to 307.88K | |
| 01-Mar-22 10:00 PM View: | Mylet Johanna Chief Financial Officer | Poseida Therapeutics, Inc. (PSTX) | 01-Mar-22 | Grant | 50,000 | -- | -- | 146% 34.23K to 84.23K | |
| 01-Mar-22 7:29 PM View: | Ingalls Kerry D. Chief Operating Officer | Poseida Therapeutics, Inc. (PSTX) | 01-Mar-22 | Grant | 50,000 | -- | -- | 2500% 2.0K to 52.0K | |
| 01-Mar-22 7:28 PM View: | Spear Matthew A. Chief Medical Officer | Poseida Therapeutics, Inc. (PSTX) | 01-Mar-22 | Grant | 50,000 | -- | -- | 81% 61.48K to 111.48K | |
| 01-Mar-22 7:30 PM View: | Leonhardt Harry J GC & Chief Compliance Officer | Poseida Therapeutics, Inc. (PSTX) | 01-Mar-22 | Grant | 50,000 | -- | -- | 100% 0 to 50.0K | |
| 01-Feb-22 9:48 PM View: | Ostertag Eric Executive Chairman Director 10% Owner | Poseida Therapeutics, Inc. (PSTX) | 01-Feb-22 | Grant | 89,500 | -- | -- | < 1% 9.32M to 9.41M | |
| 01-Feb-22 9:49 PM View: | Gergen Mark J President and CEO Director | Poseida Therapeutics, Inc. (PSTX) | 01-Feb-22 | Grant | 357,200 | -- | -- | 100% 0 to 357.2K | |
| 01-Feb-22 9:48 PM View: | Ostertag Eric Executive Chairman Director 10% Owner | Poseida Therapeutics, Inc. (PSTX) | 30-Dec-21 | Gift | 93,955 | -- | -- | (< 1%) 9.47M to 9.37M | |
| 01-Feb-22 9:48 PM View: | Ostertag Eric Executive Chairman Director 10% Owner | Poseida Therapeutics, Inc. (PSTX) | 30-Dec-21 | Gift | 48,902 | -- | -- | (< 1%) 9.37M to 9.32M | |
| 22-Dec-21 4:53 PM View: | Mylet Johanna Chief Financial Officer | Poseida Therapeutics, Inc. (PSTX) | 21-Dec-21 | Option Exercise | 5,716 | $1.59 | $9,060.87 | 20% 28.52K to 34.23K | |
| 08-Dec-21 8:38 PM View: | Spear Matthew A. Chief Medical Officer | Poseida Therapeutics, Inc. (PSTX) | 06-Dec-21 | Option Exercise | 10,000 | $1.32 | $13,220.00 | 19% 51.48K to 61.48K | |
| 07-Dec-21 6:03 AM View: | Malin Life Sciences Holding... 10% Owner | Poseida Therapeutics, Inc. (PSTX) | 06-Dec-21 | Market Purchase | 1,828 | $6.90 | $12,613.20 | < 1% 9.68M to 9.69M | (2%) |
| 02-Dec-21 6:33 PM View: | Malin Life Sciences Holding... 10% Owner | Poseida Therapeutics, Inc. (PSTX) | 02-Dec-21 | Market Purchase | 4,296 | $6.88 | $29,550.50 | < 1% 9.68M to 9.68M | (< 1%) |
| 02-Dec-21 6:33 PM View: | Malin Life Sciences Holding... 10% Owner | Poseida Therapeutics, Inc. (PSTX) | 01-Dec-21 | Market Purchase | 18,365 | $6.85 | $125,806.00 | < 1% 9.66M to 9.68M | (< 1%) |
